Medical School · Year 3 · Pediatrics · includes a quiz and discussion video

Seminar 20: Genetic and Metabolic Disorders

Unit 3: Pediatrics Clerkship

Learning Objectives

1. Recognize common chromosomal abnormalities including Down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders
2. Identify dysmorphic features and apply systematic physical examination approaches to genetic syndrome recognition
3. Describe the purpose, process, and conditions detected through newborn metabolic screening programs
4. Recognize acute and chronic presentations of inborn errors of metabolism and initiate appropriate initial management
5. Apply genetic counseling principles including inheritance patterns, recurrence risk calculation, and prenatal testing options
6. Understand the role of genetic testing modalities including karyotype, microarray, and whole exome sequencing in pediatric diagnosis

Lecture Outline

Section 1: Chromosomal Abnormalities - Trisomies

Down syndrome, caused by trisomy 21, represents the most common chromosomal abnormality compatible with survival beyond infancy, occurring in approximately 1 in 700 live births with incidence increasing significantly with advancing maternal age. The majority of cases (approximately 95%) result from meiotic nondisjunction, with the extra chromosome 21 present in all cells. Robertsonian translocation accounts for approximately 4% of cases and has implications for recurrence risk, as the parent carrying the balanced translocation has an elevated risk of having another affected child. Mosaicism, present in approximately 1% of cases, produces variable phenotypic expression depending on the proportion and distribution of trisomic cells.

The phenotypic features of Down syndrome are recognizable at birth and include a characteristic facial appearance and associated medical conditions. Facial features include upslanting palpebral fissures, epicanthal folds, flat nasal bridge, small ears, and a relatively large tongue that may protrude. Hypotonia is nearly universal in infancy and affects motor development. A single transverse palmar crease (simian crease) is present in approximately 50% of affected individuals. A widened gap between the first and second toes (sandal gap deformity) is commonly observed. These features together create a recognizable pattern, though individual features may be present in unaffected individuals.

Medical complications of Down syndrome require systematic screening and management throughout life. Congenital heart disease affects 40-50% of individuals, with atrioventricular canal defects, ventricular septal defects, and atrial septal defects being most common; echocardiography is recommended for all newborns with Down syndrome. Hypothyroidism occurs with increased frequency and requires annual TSH monitoring. Hearing loss, both conductive and sensorineural, affects a significant proportion and requires regular audiometric assessment. Atlantoaxial instability requires radiographic screening before sports participation or procedures requiring neck positioning. Leukemia risk is elevated approximately 10-20 fold, including acute lymphoblastic leukemia and acute megakaryoblastic leukemia.

Trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome) represent more severe chromosomal abnormalities with limited survival, typically to the first year of life, though some individuals survive longer with comprehensive medical care. Trisomy 18 occurs in approximately 1 in 5,000-8,000 live births and features intrauterine growth restriction, clenched fists with overlapping fingers, rocker-bottom feet, and multiple organ malformations including cardiac defects. Trisomy 13 occurs in approximately 1 in 10,000-20,000 live births and features holoprosencephaly spectrum abnormalities, cleft lip and palate, polydactyly, and cutis aplasia of the scalp. Decisions regarding medical interventions for these conditions involve careful discussions with families about goals of care and quality of life considerations.

<image>Panel A: Clinical photograph composite showing characteristic facial features of Down syndrome with labeled anatomic findings. Panel B: Karyotype image demonstrating trisomy 21 with three copies of chromosome 21 highlighted. Panel C: Comparison of physical findings in trisomy 18 versus trisomy 13 with key distinguishing features. Panel D: Survival curve showing life expectancy for different chromosomal trisomies.</image>

Section 2: Sex Chromosome Abnormalities

Turner syndrome, characterized by complete or partial monosomy of the X chromosome (45,X), affects approximately 1 in 2,000-2,500 female live births and represents the only monosomy compatible with survival to term. Many Turner syndrome conceptions are lost to early miscarriage, with the 45,X karyotype accounting for a significant proportion of first-trimester pregnancy losses. Clinical features include short stature (virtually universal without treatment), webbed neck, broad chest with widely spaced nipples, and lymphedema of the hands and feet that may be present at birth. Cardiac abnormalities, particularly bicuspid aortic valve and coarctation of the aorta, occur with increased frequency and require echocardiographic screening.

Management of Turner syndrome involves hormone replacement, surveillance for associated conditions, and supportive care. Growth hormone therapy initiated in early childhood improves adult height, with typical gains of 5-10 cm above predicted untreated height. Estrogen replacement therapy beginning around age 12-14 years induces puberty in girls with gonadal failure (streak ovaries), which affects the majority of individuals with Turner syndrome. Fertility is possible in some individuals, particularly those with mosaic Turner syndrome, though most require assisted reproductive technologies with donor oocytes. Renal abnormalities including horseshoe kidney occur with increased frequency. Hearing loss, both conductive and sensorineural, requires monitoring. Psychosocial support addresses challenges related to short stature, fertility, and social difficulties.

Klinefelter syndrome (47,XXY) affects approximately 1 in 500-1,000 males and represents the most common sex chromosome abnormality. Many affected individuals are not diagnosed until adulthood when infertility evaluation reveals small testes and azoospermia. Phenotypic features include tall stature, long limbs, gynecomastia in adolescence, small firm testes, and learning difficulties (particularly affecting language). Testosterone levels are typically low, and replacement therapy beginning in adolescence supports normal pubertal development, maintains bone health, and improves energy and mood. Fertility options include sperm extraction techniques in combination with in vitro fertilization for the minority of affected males who have residual spermatogenesis.

Other sex chromosome abnormalities include 47,XYY syndrome and 47,XXX syndrome, both of which often escape clinical detection due to relatively mild phenotypes. Males with 47,XYY tend to be tall with learning difficulties and behavioral challenges but are typically fertile and have normal sexual development. Females with 47,XXX (Triple X syndrome) may be tall with learning difficulties but are typically fertile. More complex sex chromosome abnormalities such as 48,XXXY and 49,XXXXY are associated with more significant intellectual disability and physical findings. Identification of these conditions increasingly occurs through prenatal testing or incidental findings on genetic testing performed for other indications.

<image>Panel A: Clinical features of Turner syndrome with illustration of webbed neck, broad chest, and lymphedema. Panel B: Comparison of normal female, Turner syndrome, and mosaic Turner karyotypes with phenotypic correlations. Panel C: Phenotypic features and timeline of Klinefelter syndrome from childhood through adulthood. Panel D: Comparative chart of sex chromosome aneuploidies showing karyotype, phenotype, and fertility for each.</image>

Section 3: Microdeletion and Microduplication Syndromes

Microdeletion and microduplication syndromes result from chromosomal copy number variations too small to detect on standard karyotype but identifiable through chromosomal microarray or targeted testing. DiGeorge syndrome, also known as 22q11.2 deletion syndrome or velocardiofacial syndrome, occurs in approximately 1 in 4,000 live births and produces a variable phenotype captured by the CATCH-22 mnemonic: Cardiac defects (particularly conotruncal abnormalities like tetralogy of Fallot and truncus arteriosus), Abnormal facies, Thymic hypoplasia with immunodeficiency, Cleft palate (often submucous or velopharyngeal insufficiency), and Hypocalcemia due to parathyroid hypoplasia. The deletion may be inherited or de novo, with affected parents having a 50% chance of transmitting the deletion to offspring.

Williams syndrome results from deletion at 7q11.23 and occurs in approximately 1 in 7,500-10,000 live births. The characteristic phenotype includes elfin-like facial features with a broad forehead, short nose, full cheeks, and full lips. Cardiovascular abnormalities, particularly supravalvar aortic stenosis and peripheral pulmonary stenosis, result from elastin haploinsufficiency. A distinctive personality described as "cocktail party" personality features excessive friendliness, lack of stranger anxiety, and strong verbal skills despite overall intellectual disability. Hypercalcemia in infancy may cause feeding difficulties and irritability. Connective tissue abnormalities lead to joint laxity and premature aging of skin.

Prader-Willi syndrome and Angelman syndrome represent classic examples of genomic imprinting disorders, where the phenotype depends on the parent of origin of the genetic abnormality. Prader-Willi syndrome results from loss of function of paternally expressed genes at 15q11, whether through deletion of the paternal copy, maternal uniparental disomy (inheritance of two maternal copies), or imprinting defects. The clinical presentation features severe hypotonia and feeding difficulties in infancy, followed by hyperphagia and obesity beginning in early childhood. Additional features include intellectual disability, hypogonadism, short stature, and behavioral problems including temper tantrums and obsessive-compulsive behaviors.

Angelman syndrome results from loss of function of maternally expressed UBE3A at 15q11, through maternal deletion, paternal uniparental disomy, imprinting defects, or UBE3A mutation. The phenotype is distinct from Prader-Willi syndrome despite involving the same chromosomal region, demonstrating the importance of parent-of-origin effects on gene expression. Affected individuals demonstrate severe intellectual disability with absent speech, ataxia with jerky movements, seizures, happy demeanor with frequent laughter, and a distinctive facial appearance with wide mouth and protruding tongue. EEG abnormalities are characteristic and may aid diagnosis. The difference between Prader-Willi and Angelman syndromes despite involving the same chromosomal region illustrates fundamental concepts in epigenetics and gene regulation.

<image>Panel A: CATCH-22 mnemonic illustration for DiGeorge syndrome with clinical photographs of each feature. Panel B: Facial features and personality characteristics of Williams syndrome with cardiovascular abnormalities depicted. Panel C: Comparative diagram showing genomic imprinting at 15q11 with maternal versus paternal expression patterns. Panel D: Side-by-side comparison of Prader-Willi versus Angelman syndrome phenotypes with shared genetic locus highlighted.</image>

Section 4: Single Gene Disorders and Inheritance Patterns

Mendelian inheritance patterns describe the transmission of single-gene disorders through families based on whether the gene is located on an autosome or sex chromosome and whether one or two mutated copies are required to produce the phenotype. Autosomal dominant disorders require only one mutated copy of the gene to cause disease, with affected individuals typically having one affected parent and a 50% chance of transmitting the mutation to each offspring. Autosomal recessive disorders require two mutated copies, with carrier parents having a 25% chance of an affected child with each pregnancy. X-linked recessive disorders primarily affect males who inherit a mutated copy on their single X chromosome, while carrier females are typically unaffected but transmit the mutation to 50% of sons.

Neurofibromatosis type 1 represents one of the most common autosomal dominant disorders, affecting approximately 1 in 3,000 individuals. Diagnosis requires two or more of the following criteria: six or more cafe-au-lait macules (greater than 5 mm prepubertally or greater than 15 mm postpubertally), axillary or inguinal freckling, two or more neurofibromas or one plexiform neurofibroma, two or more Lisch nodules (iris hamartomas), optic pathway glioma, distinctive bony lesions (sphenoid dysplasia, tibial pseudarthrosis), or a first-degree relative with NF1. Complications include learning disabilities, skeletal abnormalities, and increased risk of malignancies. Approximately 50% of cases represent new mutations, with affected individuals then transmitting the mutation with 50% probability to offspring.

Cystic fibrosis, caused by mutations in the CFTR gene, represents the most common life-limiting autosomal recessive disorder in individuals of European ancestry. Classic cystic fibrosis presents with progressive pulmonary disease due to thick, tenacious secretions, pancreatic insufficiency with malabsorption, and elevated sweat chloride. Males are typically infertile due to congenital bilateral absence of the vas deferens. Newborn screening identifies affected infants before clinical symptoms develop, allowing early intervention with pancreatic enzyme replacement, airway clearance therapies, and nutritional support. CFTR modulator therapies have transformed outcomes for individuals with specific mutations, with triple therapy (elexacaftor/tezacaftor/ivacaftor) benefiting approximately 90% of affected individuals.

Duchenne muscular dystrophy, caused by mutations in the dystrophin gene on the X chromosome, represents the most common muscular dystrophy of childhood. Affected boys develop progressive weakness beginning in early childhood, with delayed walking, difficulty climbing stairs, and the characteristic Gower sign (using arms to climb up the legs when rising from the floor). Elevated creatine kinase levels are markedly elevated and may be detected incidentally. Wheelchair dependence typically occurs by age 12, with progressive respiratory and cardiac involvement. Corticosteroid therapy prolongs ambulation and delays complications. Female carriers may exhibit mild weakness and cardiomyopathy and should be monitored. Emerging gene therapies offer hope for disease modification in affected individuals.

<image>Panel A: Pedigree diagrams showing inheritance patterns for autosomal dominant, autosomal recessive, and X-linked recessive disorders. Panel B: Clinical photographs of neurofibromatosis type 1 features including cafe-au-lait spots, axillary freckling, and Lisch nodules. Panel C: Pathophysiology of cystic fibrosis showing CFTR dysfunction in airways and pancreas with resulting clinical manifestations. Panel D: Progressive muscular dystrophy timeline showing clinical features and interventions across the lifespan.</image>

Section 5: Dysmorphology and Physical Examination

Dysmorphology terminology provides precise language for describing structural abnormalities and understanding their developmental origins. A malformation represents a primary structural defect arising from an intrinsically abnormal developmental process, such as a ventricular septal defect or cleft lip. A deformation results from abnormal mechanical forces on a previously normal structure, such as clubfoot from intrauterine constraint. A disruption involves breakdown of a previously normal structure, such as an amniotic band causing limb amputation. A dysplasia describes abnormal organization of cells into tissues, such as skeletal dysplasias affecting bone formation. A sequence describes a cascade of abnormalities stemming from a single primary defect, while a syndrome describes multiple abnormalities with a common underlying etiology.

Minor anomalies are subtle physical findings that occur in the general population with low frequency but may suggest an underlying genetic condition when multiple are present. Examples include preauricular pits or tags, epicanthal folds, single transverse palmar crease, fifth finger clinodactyly, and sandal gap deformity. The presence of three or more minor anomalies significantly increases the likelihood of a major anomaly or underlying syndrome and warrants further evaluation. Minor anomalies serve as external clues to developmental disturbances during embryogenesis that may have affected internal organ development as well. Recognition of these findings prompts consideration of the timing and nature of the developmental perturbation.

The systematic dysmorphology examination proceeds from head to toe with attention to both major and minor features. Head examination assesses shape, size (microcephaly or macrocephaly), fontanelle characteristics, and presence of ridging or craniosynostosis. Facial assessment evaluates spacing and positioning of features, including palpebral fissure orientation, intercanthal and interpupillary distances, nasal structure, philtrum length and shape, and ear position, rotation, and morphology. Extremity examination notes limb proportions (rhizomelic, mesomelic, or acromelic shortening), digit number and configuration, and joint mobility. Skin findings including cafe-au-lait spots, hypopigmented macules, and capillary malformations may indicate specific syndromes.

Measurements and photography document findings for comparison with normative data and specialist consultation. Accurate measurement of head circumference, height, weight, arm span, and inner/outer canthal distances allows comparison with published norms and syndrome-specific growth charts. Standardized photographs with appropriate consent document findings for medical records and facilitate remote consultation with genetics specialists. The combination of clinical findings, family history, and developmental assessment guides genetic testing selection, with chromosomal microarray typically representing the first-line genetic test for unexplained developmental delay, intellectual disability, or multiple congenital anomalies.

<image>Panel A: Diagram illustrating the differences between malformation, deformation, disruption, and dysplasia with clinical examples. Panel B: Facial measurement landmarks showing standard measurements for dysmorphology assessment. Panel C: Grid of minor anomaly examples with population frequency and syndrome associations. Panel D: Systematic physical examination flowchart from head to toe for dysmorphology evaluation.</image>

Section 6: Newborn Metabolic Screening

Newborn metabolic screening represents a public health program designed to identify infants with treatable conditions before symptoms develop, preventing irreversible harm through early intervention. The principles underlying screening program development include high disease burden or severity, availability of effective treatment that changes outcomes, adequate sensitivity and specificity of screening tests, and acceptable cost-benefit ratio. The number of conditions screened varies by state and country, with the Recommended Uniform Screening Panel in the United States currently including over 30 core conditions and numerous secondary conditions. Early detection transforms outcomes for many conditions that would otherwise cause severe disability or death.

The screening process involves collection of blood spots on filter paper, typically obtained by heel stick at 24-48 hours of life to allow metabolic perturbations to manifest after transition from placental metabolism. Testing methodologies include tandem mass spectrometry for amino acid disorders, fatty acid oxidation disorders, and organic acidemias; enzyme assays for specific conditions like biotinidase deficiency; hormone levels for congenital hypothyroidism and congenital adrenal hyperplasia; hemoglobin electrophoresis for hemoglobinopathies; and immunoreactive trypsinogen for cystic fibrosis. Premature infants and those with early discharge may require repeat screening. Results require several days for processing, with critical results communicated immediately to ensure rapid confirmatory testing and treatment initiation.

Conditions detected through newborn screening span multiple categories of metabolic disease. Amino acid disorders include phenylketonuria, maple syrup urine disease, homocystinuria, and tyrosinemia. Fatty acid oxidation disorders include medium-chain acyl-CoA dehydrogenase deficiency, very long-chain acyl-CoA dehydrogenase deficiency, and carnitine transport defects. Organic acidemias include propionic acidemia, methylmalonic acidemia, and isovaleric acidemia. Endocrine disorders include congenital hypothyroidism and congenital adrenal hyperplasia. Hemoglobinopathies including sickle cell disease and thalassemias are detected. Additional conditions include galactosemia, biotinidase deficiency, cystic fibrosis, and severe combined immunodeficiency.

Abnormal screening results require prompt confirmatory testing while avoiding premature labeling or family anxiety from false-positive results. The positive predictive value of screening tests varies by condition, with many abnormal screens representing false positives, particularly for conditions with high screening thresholds intended to maximize sensitivity. Confirmatory testing methodology depends on the suspected condition: plasma amino acids for amino acid disorders, acylcarnitine profile for fatty acid oxidation and organic acid disorders, hemoglobin electrophoresis for hemoglobinopathies, hormone levels for endocrine conditions. Communication with families requires balancing urgency for evaluation with avoidance of unnecessary alarm while results are pending.

<image>Panel A: Heel stick technique illustration showing proper blood spot collection on filter paper cards. Panel B: Diagram of tandem mass spectrometry principles showing metabolite identification approach. Panel C: Categorical organization of newborn screening conditions with example disorders in each category. Panel D: Workflow from abnormal screen to confirmatory testing and treatment initiation with timeline.</image>

Section 7: Inborn Errors of Metabolism - Clinical Presentations

Acute presentations of inborn errors of metabolism may mimic sepsis or other common neonatal conditions, requiring high clinical suspicion for appropriate diagnosis and management. The classically ill newborn with lethargy, poor feeding, vomiting, and encephalopathy after an initial period of normal behavior following birth should prompt consideration of metabolic disease. This symptom-free interval reflects the transition from placental metabolism, where the maternal circulation clears toxic metabolites, to independent metabolism, where enzyme deficiencies lead to accumulation. Key laboratory findings suggesting metabolic disease include unexplained metabolic acidosis with elevated anion gap, hypoglycemia (particularly with inappropriate ketosis), and hyperammonemia.

Triggering events precipitate metabolic decompensation in susceptible individuals by increasing metabolic demands or providing excess substrate. Fasting stress depletes glycogen stores and increases lipolysis, precipitating decompensation in fatty acid oxidation disorders and glycogen storage diseases. Protein intake provides amino acid substrate that cannot be metabolized in urea cycle disorders and organic acidemias. Intercurrent illness increases catabolism and metabolic demand while often reducing oral intake. Introduction of lactose or sucrose-containing formula may precipitate symptoms in galactosemia or hereditary fructose intolerance. Recognition of these triggers helps identify at-risk presentations and guides preventive management for known affected individuals.

Chronic presentations of inborn errors of metabolism may manifest as failure to thrive, developmental delay, or organ-specific dysfunction developing gradually over months to years. Hepatomegaly suggests glycogen storage diseases or lysosomal storage disorders. Cardiomyopathy occurs in fatty acid oxidation disorders and Pompe disease. Developmental regression, with loss of previously acquired skills, characterizes many storage disorders including the mucopolysaccharidoses, metachromatic leukodystrophy, and Krabbe disease. Unusual odors may provide diagnostic clues: maple syrup urine disease produces a sweet, burnt sugar odor; isovaleric acidemia produces a sweaty feet smell; phenylketonuria produces a musty or mousy odor.

Red flags that should prompt metabolic evaluation include consanguinity (increasing autosomal recessive disease risk), previous unexplained sibling death, recurrent episodes of unexplained encephalopathy or acidosis, developmental regression, and multi-organ involvement without clear etiology. Initial metabolic evaluation includes blood glucose, electrolytes with anion gap calculation, blood gas analysis, lactate, ammonia, and urine ketones. Specialized testing includes plasma amino acids, urine organic acids, and acylcarnitine profile. Samples should be obtained during acute illness when metabolic derangements are most pronounced; some abnormalities may normalize during recovery, making retrospective diagnosis difficult.

<image>Panel A: Timeline diagram showing symptom-free interval followed by acute decompensation with pathophysiologic explanation. Panel B: Precipitating factors chart showing triggers and their associated metabolic conditions. Panel C: Organ system involvement patterns for different categories of metabolic disease. Panel D: Red flags checklist with associated metabolic conditions and initial testing approach.</image>

Section 8: Specific Metabolic Disorders

Phenylketonuria, caused by deficiency of phenylalanine hydroxylase, represents the prototype of amino acid disorders detected by newborn screening and treated with dietary modification. Untreated PKU causes severe intellectual disability, seizures, behavioral problems, and a musty body odor from accumulated phenylalanine metabolites. Affected infants appear normal at birth because maternal phenylalanine hydroxylase metabolizes phenylalanine during pregnancy. Newborn screening detects elevated phenylalanine before symptoms develop. Treatment with a low-phenylalanine diet prevents neurological damage when initiated early and maintained throughout life. Dietary phenylalanine must be restricted while providing adequate tyrosine, which becomes essential when phenylalanine cannot be converted. Maternal PKU syndrome occurs when women with PKU have elevated phenylalanine during pregnancy, causing congenital heart defects, microcephaly, and intellectual disability in their offspring regardless of fetal genotype.

Medium-chain acyl-CoA dehydrogenase deficiency, the most common fatty acid oxidation disorder, illustrates the importance of recognizing metabolic disease in acute presentations. MCAD deficiency impairs the ability to metabolize medium-chain fatty acids during fasting, when fat becomes the primary energy source. Without intervention, affected individuals may present with hypoketotic hypoglycemia during intercurrent illness or prolonged fasting, potentially progressing to coma and death. Newborn screening identifies affected infants through elevated octanoylcarnitine (C8) on acylcarnitine profile before any symptomatic episode occurs. Management involves avoidance of prolonged fasting (maximum 8-12 hours depending on age), provision of glucose during illness, and emergency protocols for sick days. With appropriate precautions, affected individuals have normal development and life expectancy.

Galactosemia, caused by deficiency of galactose-1-phosphate uridyltransferase, presents in the neonatal period after lactose-containing feeds (breast milk or standard formula) introduce galactose. Classic findings include feeding difficulties, jaundice, hepatomegaly, and increased susceptibility to E. coli sepsis. Cataracts develop if diagnosis is delayed. Reducing substances in urine (galactose is a reducing sugar) may provide a clue, though specific enzymatic testing is confirmatory. Treatment involves immediate removal of galactose from the diet, with soy-based or elemental formulas replacing lactose-containing feedings. Despite dietary treatment, many individuals develop complications including cognitive difficulties, speech problems, and ovarian failure in females, suggesting toxicity from in utero galactose exposure or incomplete pathway blockade.

Glycogen storage diseases represent a group of disorders affecting glycogen synthesis, storage, or breakdown, with type I (von Gierke disease) and type II (Pompe disease) representing distinct phenotypes. Type I glycogen storage disease presents with hepatomegaly, hypoglycemia during fasting, and metabolic derangements including lactic acidosis, hyperlipidemia, and hyperuricemia. Management involves frequent feedings and uncooked cornstarch to maintain glucose levels. Pompe disease (type II) affects lysosomal acid maltase and presents with severe hypotonia, cardiomyopathy, and respiratory failure in the infantile form. Enzyme replacement therapy has transformed outcomes for Pompe disease, with earlier treatment associated with better outcomes, leading to inclusion in newborn screening programs.

<image>Panel A: Phenylalanine metabolism pathway showing site of enzyme deficiency and dietary intervention in PKU. Panel B: Fatty acid oxidation pathway with MCAD role highlighted and consequences of deficiency during fasting. Panel C: Galactose metabolism showing toxic metabolite accumulation and clinical manifestations. Panel D: Glycogen metabolism diagram comparing type I and type II glycogen storage diseases.</image>

Section 9: Urea Cycle Disorders

The urea cycle converts nitrogen from protein metabolism to urea for renal excretion, with defects in any enzyme of the cycle leading to hyperammonemia and potential brain damage. The cycle involves six enzymes, with ornithine transcarbamylase (OTC) deficiency being the most common, inherited in an X-linked pattern. Male infants with complete OTC deficiency present in the neonatal period with severe hyperammonemia, while heterozygous females and males with partial deficiency may present later in life during metabolic stress. Other urea cycle defects include carbamoyl phosphate synthetase I deficiency, argininosuccinic aciduria, and citrullinemia, all inherited in autosomal recessive patterns.

Clinical presentation of acute hyperammonemia includes progressive encephalopathy manifesting as lethargy, poor feeding, vomiting, hypothermia, and respiratory alkalosis (from central hyperventilation stimulated by ammonia). Initial symptoms may be attributed to sepsis or other common neonatal conditions, delaying diagnosis. As ammonia levels rise, seizures, coma, and cerebral edema develop. Ammonia levels above 200 micromol/L indicate severe toxicity requiring immediate intervention. The diagnosis should be considered in any encephalopathic infant, particularly with respiratory alkalosis (rather than the acidosis typical of organic acidemias) and without evidence of infection. Plasma amino acid analysis reveals specific patterns diagnostic of individual urea cycle defects.

Acute management of hyperammonemia prioritizes stopping protein catabolism and removing accumulated ammonia. Protein intake should be immediately discontinued to eliminate nitrogen substrate. High-calorie glucose infusion (typically 10% dextrose at 1.5 times maintenance) provides energy to prevent catabolism. Nitrogen-scavenging medications including sodium benzoate and sodium phenylacetate (available as the combination product Ammonul) provide alternative pathways for nitrogen excretion. Hemodialysis is the most effective method for rapid ammonia removal when levels are critically elevated or not responding to medical management. Arginine supplementation replaces the amino acid that becomes essential when the cycle is blocked, though it is contraindicated in arginase deficiency.

Long-term management of urea cycle disorders aims to prevent recurrent hyperammonemic episodes while supporting normal growth and development. Dietary protein restriction limits nitrogen intake while providing essential amino acids; specialized metabolic formulas may be required. Oral nitrogen scavengers (sodium benzoate, sodium phenylbutyrate, glycerol phenylbutyrate) are continued chronically. Citrulline or arginine supplementation addresses deficiencies caused by cycle interruption. Sick-day protocols provide guidance for managing intercurrent illness with increased glucose intake, possible protein restriction, and low threshold for medical evaluation. Liver transplantation is curative for many urea cycle disorders, as the liver contains the urea cycle enzymes, and may be considered for severe cases or those with recurrent decompensation despite optimal medical management.

<image>Panel A: Urea cycle enzyme diagram showing sites of defects for each disorder with characteristic amino acid patterns. Panel B: Clinical presentation timeline of acute hyperammonemic encephalopathy with progressive symptoms. Panel C: Acute management algorithm for hyperammonemia with medication dosing and dialysis indications. Panel D: Long-term management components including dietary, pharmacologic, and monitoring elements.</image>

Section 10: Genetic Counseling and Testing

Genetic counseling provides comprehensive information and support to individuals and families affected by or at risk for genetic conditions, facilitating informed decision-making while respecting personal values and autonomy. The genetic counseling process includes diagnosis confirmation or establishment, explanation of the condition's natural history and management, inheritance pattern determination, recurrence risk calculation, discussion of testing options for family members, and provision of psychosocial support. Non-directiveness represents a core principle, with counselors providing complete information while allowing families to make their own reproductive and medical decisions. Genetic counselors and clinical geneticists work collaboratively with referring physicians to provide these services.

Recurrence risk calculation depends on the inheritance pattern of the condition and the family's specific situation. For autosomal dominant conditions with a de novo mutation in an affected child, recurrence risk is low (approximately 1%) due to potential gonadal mosaicism, while an affected parent transmits the mutation to 50% of offspring. For autosomal recessive conditions where both parents are carriers, each pregnancy has a 25% risk of an affected child, 50% risk of a carrier, and 25% risk of an unaffected non-carrier. X-linked recessive conditions transmitted by carrier mothers result in 50% of sons being affected and 50% of daughters being carriers. Chromosomal abnormalities have variable recurrence risk depending on whether they arose from non-disjunction (generally low recurrence adjusted for maternal age) or parental balanced translocation (recurrence depends on specific translocation).

Prenatal genetic testing options include both screening and diagnostic approaches at various gestational ages. Cell-free DNA screening (non-invasive prenatal testing) can be performed from 10 weeks gestation and screens for common trisomies with high sensitivity and specificity but requires confirmatory testing for positive results. First-trimester combined screening includes nuchal translucency ultrasound with maternal serum markers. Chorionic villus sampling at 10-13 weeks provides fetal cells for chromosome analysis or molecular testing. Amniocentesis at 15-20 weeks similarly provides fetal cells with lower procedural risk than CVS. Preimplantation genetic testing allows embryo testing during in vitro fertilization cycles for families with known genetic conditions.

Genetic testing technologies have evolved rapidly, providing increasingly comprehensive diagnostic capabilities. Karyotype analysis identifies aneuploidy and large chromosomal rearrangements but cannot detect smaller copy number variants or single-gene mutations. Chromosomal microarray serves as a first-line test for developmental delay, intellectual disability, and multiple congenital anomalies, detecting copy number variants at much higher resolution than karyotype. FISH analysis provides rapid results for specific chromosomal regions when a particular syndrome is suspected. Whole exome sequencing analyzes the protein-coding regions of all genes and has become increasingly important for undiagnosed genetic conditions after microarray is unrevealing. Gene panels target groups of genes associated with specific phenotypes, providing efficient testing when a category of disorder is suspected.

<image>Panel A: Genetic counseling process flowchart showing components from initial consultation through follow-up. Panel B: Recurrence risk diagrams for autosomal dominant, autosomal recessive, and X-linked recessive inheritance. Panel C: Prenatal testing timeline showing options available at each gestational age with indications. Panel D: Genetic testing technology comparison showing resolution, types of variants detected, and appropriate indications for each.</image>

Summary

• Down syndrome (trisomy 21) is the most common chromosomal abnormality, characterized by distinctive facial features, hypotonia, and associated conditions requiring echocardiography, thyroid monitoring, and hearing assessment
• Turner syndrome (45,X) presents in females with short stature, webbed neck, and coarctation of aorta requiring growth hormone and estrogen replacement therapy
• 22q11.2 deletion syndrome (DiGeorge) features CATCH-22 findings: Cardiac, Abnormal facies, Thymic hypoplasia, Cleft palate, Hypocalcemia
• Newborn metabolic screening detects treatable conditions at 24-48 hours of life before symptoms develop; abnormal screens require confirmatory testing
• Inborn errors of metabolism may present acutely with encephalopathy, acidosis, and hyperammonemia, often triggered by fasting, protein intake, or illness
• Phenylketonuria is treated with a low-phenylalanine diet to prevent intellectual disability; maternal PKU requires strict control during pregnancy
• MCAD deficiency presents with hypoketotic hypoglycemia during fasting; management involves avoidance of prolonged fasting
• Urea cycle disorders cause hyperammonemia treated with protein restriction, nitrogen scavengers, and hemodialysis for severe cases
• Chromosomal microarray is the first-line genetic test for unexplained developmental delay, intellectual disability, or multiple congenital anomalies
• Genetic counseling provides non-directive information about diagnosis, inheritance, recurrence risk, and prenatal testing options

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown